Helio Caiaffa Filho

Helio Caiaffa Filho

Auto-generated profile, based on publicly available information

Helio Caiaffa Filho

Molecular Biology Division – University of Sao Paulo, São Paulo, Brazil

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2019 in Journal of Intensive Care
Verified
Journal Article
Open access
PDF file
CRCristhieni Rodrigues
Cristhieni Rodrigues
Rinaldo Focaccia Focaccia SicilianoRinaldo Focaccia Focaccia Siciliano
Rinaldo Focaccia Focaccia Siciliano
HFHelio Caiaffa Filho
Helio Caiaffa Filho
CCCecília Eugenia Charbel
Cecília Eugenia Charbel
LSLuciane de Carvalho Sarahyba da Silva
Luciane de Carvalho Sarahyba da Silva
TSTania Mara Varejão Strabelli
Tania Mara Varejão Strabelli
Appropriate use of antimicrobials is essential to improve outcomes in sepsis. The aim of this study was to determine whether the use of a rapid molecular blood test—SeptiFast (SF) reduces the antibiotic consumption through early de-escalation in patients with nosocomial sepsis compared with conventional blood cultures (BCs). This was a prospective, randomized, superiority, controlled trial conducted at Sao Paulo Heart Institute in the period October 2012–May 2016. Adult patients admitted to the hospital for at least 48 h with a diagnosis of nosocomial sepsis underwent microorganism identification by both SF test and BCs. Patients randomized into the intervention group received antibiotic therapy adjustment according to the results of SF. Patients randomized into the control group received standard antibiotic adjustment according to the results of BCs. The primary endpoint was antimicrobial consumption during the first 14 days after randomization. A total of 200 patients were included (100 in each group). The intention to treat analysis found no significant differences in median antibiotic consumption. In the subgroup of patients with positive SF and blood cultures (19 and 25 respectively), we found a statistically significant reduction in the median antimicrobial consumption which was 1429 (1071–2000) days of therapy (DOT)/1000 patients-day in the intervention group and 1889 (1357–2563) DOT/1000 patients-day in the control group (p = 0.017), in the median time of antimicrobial de-escalation (8 versus 54 h—p < 0.001), in the duration of antimicrobial therapy (p = 0.039) and in anti-gram-positive antimicrobial costs (p = 0.002). Microorganism identification was possible in 24.5% of patients (45/184) by SF and 21.2% (39/184) by BC (p = 0.45). This randomized clinical trial showed that the use of a rapid molecular-based pathogen identification test does not reduce the median antibiotic consumption in nosocomial sepsis. However, in patients with positive microbiological tests, the use of SeptiFast reduced antimicrobial consumption through early de-escalation compared to conventional blood cultures. These results were driven by a reduction in the consumption of antimicrobials used for Gram-positive bacteria. The trial was registered at ClinicalTrials.gov ( NCT 01450358 ) on 12th October 2011